98%
921
2 minutes
20
Background: Although previous studies suggested associations between psoriasis and atopic dermatitis (AD), the directionality and causality of these relationships remain controversial. This study employed bidirectional Mendelian randomization to investigate the potential causal relationships between these two inflammatory skin conditions.
Methods: Genome-wide association statistics were obtained for psoriasis and AD from large-scale consortia and meta-analyses of genome-wide association studies. Inverse-variance weighting, as the primary analysis, was combined with five complementary sensitivity analyses to evaluate the robustness and potential pleiotropy of the data. Additionally, we performed gene mapping of psoriasis-associated single-nucleotide polymorphisms and subsequent pathway analysis to further elucidate the potential relationships.
Results: Genetic predisposition to psoriasis was significantly associated with a decreased risk of AD (odds ratio = 0.876; 95% confidence interval = 0.834-0.921; p = 1.6 × 10-7). Conversely, genetic predisposition to AD did not affect the risk of psoriasis. The associations remained consistent across multiple sensitivity analyses, and no evidence of horizontal pleiotropy was observed. Gene mapping identified eight key genes (ENSG00000249738, ENSG00000291336, ENSG00000291338, ENSG00000285703, OR2W1-AS1, HLA-DQA1, FBXL18, and nitric oxide synthase 2 (NOS2) located on chromosomes 5, 6, 7 and 17. Notably, NOS2 emerged as a core gene involved in key biological processes, including the TCR signaling pathway and protein metabolism.
Conclusions: This comprehensive MR study provided evidence of the protective causal effect of psoriasis on the risk of AD, whereas no reverse causal relationship was noted. These findings enhanced our understanding of the relationship between psoriasis and Ad and identified potential implications for their clinical management.
Download full-text PDF |
Source |
---|---|
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322602 | PLOS |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416699 | PMC |
Chem Biodivers
September 2025
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Bologna, Italy.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.
View Article and Find Full Text PDFRheumatol Int
September 2025
Division of Rheumatology and Immunology, Department of PMR, , Sakarya University School of Medicine, Sakarya, Turkey.
To identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within ± 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO).
View Article and Find Full Text PDFJ Dermatol
September 2025
Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
The long-term impact of biologic therapy on malignancy risk in patients with psoriasis remains unclear. Given the chronic nature of psoriasis and the increasing use of biologics, understanding their long-term safety profile is crucial. This study aimed to compare the incidence of malignancy between patients receiving continuous biologic therapy and those treated with topical monotherapy.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Health Statistics, School of Public Health, Shandong Second Medical University, Weifang, Shandong, China.
Both psoriasis and autoimmune thyroid diseases are characterized by chronic inflammation. The previous studies indicated a potential association between psoriasis and autoimmune thyroid diseases. However, the direction and nature of these relationships remain unclear.
View Article and Find Full Text PDF